Ocugen (NASDAQ: OCGN) is one of 29 publicly-traded companies in the “Surgical appliances & supplies” industry, but how does it compare to its competitors? We will compare Ocugen to related businesses based on the strength of its institutional ownership, profitability, earnings, dividends, valuation, risk and analyst recommendations.
Volatility & Risk
Ocugen has a beta of 3, indicating that its stock price is 200% more volatile than the S&P 500. Comparatively, Ocugen’s competitors have a beta of 1.13, indicating that their average stock price is 13% more volatile than the S&P 500.
This is a summary of current ratings and price targets for Ocugen and its competitors, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
As a group, “Surgical appliances & supplies” companies have a potential upside of 11.86%. Given Ocugen’s competitors higher probable upside, analysts clearly believe Ocugen has less favorable growth aspects than its competitors.
Valuation and Earnings
This table compares Ocugen and its competitors revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Ocugen Competitors||$1.39 billion||$142.47 million||17.13|
Ocugen’s competitors have higher revenue and earnings than Ocugen. Ocugen is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Insider and Institutional Ownership
56.3% of shares of all “Surgical appliances & supplies” companies are held by institutional investors. 19.7% of Ocugen shares are held by insiders. Comparatively, 8.2% of shares of all “Surgical appliances & supplies” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
This table compares Ocugen and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Ocugen Company Profile
Ocugen, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases. The company offers an ophthalmology portfolio that includes novel gene therapies, biologics, and small molecules, as well as targets a range of retinal and ocular surface diseases. Its pipeline includes OCU400 and OCU410 for the treatment of inherited retinal disorders; OCU200 for the treatment of wet-AMD, DME, and diabetic retinopathy; OCU100 for retinitis pigmentosa; and OCU300, which is in Phase III clinical trial for the treatment of ocular graft versus host diseases. The company based in Malvern, Pennsylvania.
Receive News & Ratings for Ocugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocugen and related companies with MarketBeat.com's FREE daily email newsletter.